From: Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs
Targeted molecular agents | Primary molecular target | FDA approved cancer sites | Response rate in ovarian cancer | Toxicities |
---|---|---|---|---|
Imatinib | KIT, PDGF-R (TKI) | GIST | Fatigue, diarrhea, rash, nausea, cardiotoxicity, granulocytopenia | |
Trastuzumab | HER-2 (mAB) | Breast, gastroeosphageal | 7.3% ORR [22] | Fatigue, diarrhea, rash, cardiotoxicity, anemia, dyspnea, neutropenia |
Pertuzumab | HER-2 (TKI) | Breast cancer | 4.3% ORR, 6.8% SD [23] | Diarrhea, neutropenia, nausea, LV dysfunction, VTE, vomiting, renal failure |
Bevacizumab | VEGF (mAB) | Glioblastoma, NSCLC, mBreast, mCRC, mRCC | Fatigue, diarrhea, anorexia, hypertension, gastrointestinal perforation, proteinuria, hemorrhage, congestive heart failure, arterial thromboembolism, wound healing problems | |
Gefitinib | EGFR (TKI) | NSCLC | Diarrhea, rash, nausea, vomiting, mucositis, dyspnea | |
Erlotinib | EGFR (TKI) | NSCLC | 6% ORR, 44% SD [29] | Fatigue, diarrhea, rash, anorexia |
Temsirolimus | mTOR inhibitor | RCC | 9.3% ORR, 24.1% 6m PFS [30] | Fatigue, diarrhea, rash, nausea, anorexia, stomatitis, anemia, hypertension, dyspnea |
Vandetanib | EGFR, TEGF, RET (TKI) | Medullary thyroid cancer | 0% ORR/SD [31] | Diarrhea, rash, hypertension, proteinuria, asymptomatic, QT prolongation |
Sorafenib | VEGF, PDGF, c-Raf (TKI, Raf KI) | RCC, hepatocellular carcinoma | 3% ORR, 34% SD [32] | Fatigue, diarrhea, rash, nausea, vomiting, anorexia, hypothyroidism, cardiotoxicity, hand–foot syndrome |
Sunitinib | VEGF, PDGF, KIT (TKI) | RCC, GIST, pancreatic neuroendocrine tumor | 3% ORR, 53% SD [33] | Fatigue, diarrhea, nausea, vomiting, hypothyroidism, hypertension, cardiotoxicity |
Pazopanib | TKI VEGF, PDGFR (TKI) | RCC, soft tissue sarcoma | 31% ORR, 56% SD (Ca-125 response) [34] | Fatigue, diarrhea, nausea, anorexia, hypertension, abdominal pain, arrhythmia, hepatotoxicity, hemorrhage |
Lapatinib | HER2, EGFR (TKI) | Breast Cancer | 0% ORR, 8 SD [35] | QT prolongation, CYP3A4, GI toxicity |
Olaparib | PARP inbibitor | n/a | fatigue, somnolence, nausea, loss of appetite, thrombocytopenia |